Blossom Enterprise

Drug-development intelligence briefings

Quarterly analysis of indication activity, developer programmes, evidence maturity, and upcoming catalysts. Each briefing exposes a public sample; the full evidence ledger and appendix require Enterprise access.

Current and archive

Quarterly briefings

2 available

Latest briefing

Q2 2026

Preview

A quarterly competitive intelligence briefing for developer strategy teams, with a complete Anxiety / GAD sample section and selected market signals.

Coverage
7 indication areas
Public sample
Anxiety / GAD

Reporting window: Apr 1, 2026 to Jun 30, 2026

Public sample and gated full reportOpen briefing

Archive

Q1 2026

Published

A quarterly competitive intelligence briefing for developer strategy teams, with a complete Anxiety / GAD sample section and selected market signals.

Coverage
7 indication areas
Public sample
Anxiety / GAD

Reporting window: Jan 1, 2026 to Mar 31, 2026

Public sample and gated full reportOpen briefing